麗珠醫藥(01513.HK)擬與健康元共同出資設立合資公司河南研究院
格隆匯 11 月 30日丨麗珠醫藥(01513.HK)宣佈,於2020年11月30日,公司控股附屬新北江製藥與健康元全資附屬公司焦作健康元訂立共同投資協議,據此,新北江製藥與焦作健康元同意共同以現金方式投資設立合資公司河南研究院,其中新北江製藥出資人民幣4900萬元,佔比49%,焦作健康元出資人民幣5100萬元,佔比51%。
截至最後實際可行日期,健康元直接及間接持有公司已發行股本總額約44.35%股權,而焦作健康元由健康元直接及間接持有100.00%權益。
董事認為,設立合資公司是為了集聚和強化外部研發人才資源和研發能力,重點集中在生物醫藥中間體及高端特色原料藥的創新研發工作上。設立合資公司將有利於促進公司原料藥業務研發實力的提升與新方向、新領域佈局,進而提高公司的核心競爭力及可持續發展實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.